chufangao/CTO huggingface dataset:
Clinical trial NCT04896112: A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
Official title: An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients With Malignant Myeloid Hematologic Neoplasms
Sponsor: Lynk Pharmaceuticals Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 10.0
Start date: 2021-04-08
Primary completion date: 2022-10-20
Completion date: 2022-10-20
Plan to share individual participant data: NO
Clinical trial NCT03444753: An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Official title: A Phase I Study of BMS-986299 as Monotherapy and in Combination With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: business objectives have changed
Enrollment: 82.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-05
Primary completion date: 2022-02-14
Completion date: 2022-02-14
Clinical trial NCT02771626: Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Official title: A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Sponsor: Calithera Biosciences, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: lack of efficacy
Enrollment: 118.0 (ACTUAL)
Number of arms: 6.0
Start date: 2016-08-01
Primary completion date: 2020-04-24
Completion date: 2020-04-24
Plan to share individual participant data: NO
Clinical trial NCT04333628: Chloroquine for Mild Symptomatic and Asymptomatic COVID-19
Official title: Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial
Sponsor: HaEmek Medical Center, Israel (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Teminated due to changes in treatment guidelines .
Enrollment: 5.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-01
Primary completion date: 2020-09-01
Completion date: 2020-09-01
Plan to share individual participant data: NO
Clinical trial NCT04526509: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Official title: Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated due to a change in GSK's R\&D priorities.
Enrollment: 12.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-12-21
Primary completion date: 2023-06-08
Completion date: 2023-06-08
Baseline population: Intent-to-treat (ITT) population that included all participants who started leukapheresis procedure.
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT04835168: Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis
Official title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis
Sponsor: NImmune Biopharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: The closure of the study is driven by the decision to redesign the study protocol for future studies.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-01-30
Primary completion date: 2022-04-30
Completion date: 2022-06-30
Plan to share individual participant data: NO
Clinical trial NCT04586920: A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants
Official title: A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3509754 in Healthy Non-Japanese and Japanese Participants
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated due to safety findings
Enrollment: 104.0 (ACTUAL)
Number of arms: 8.0
Start date: 2020-10-20
Primary completion date: 2022-10-14
Completion date: 2022-10-14
Plan to share individual participant data: NO
Clinical trial NCT02278120: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Official title: A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Acronym: MONALEESA-7
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 672.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-11-20
Primary completion date: 2017-08-21
Completion date: 2023-04-20
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03517995: Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention
Official title: Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Grant not approved
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-30
Primary completion date: 2021-12-31
Completion date: 2022-12-31
Clinical trial NCT03884517: Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer
Official title: An Open, Escalating Phase I Clinical Trial of BAT8003 (for Injection) on the Safety, Tolerability and Pharmacokinetics for Patients With Advanced Epithelial Cancer
Sponsor: Bio-Thera Solutions (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Considering that the safety risk will affect the subsequent development, it is decided to terminate the test voluntarily
Enrollment: 5.0 (ACTUAL)
Number of arms: 9.0
Start date: 2019-03-15
Primary completion date: 2021-02-08
Completion date: 2021-02-08
Clinical trial NCT02054520: Immunotherapy Study for Patients With Stage IV Melanoma
Official title: A Phase 2b Study of Immune Checkpoint Inhibition With or Without Dorgenmeltucel-L (HyperAcute Melanoma) Immunotherapy for Stage IV Melanoma Patients
Sponsor: Lumos Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Withdrawal of IND
Enrollment: 47.0 (ACTUAL)
Number of arms: 6.0
Start date: 2014-06-30
Primary completion date: 2018-04-05
Completion date: 2021-01-05
Limitations and caveats: Early termination leading to small numbers of subjects analyzed. The enrollment and treatment phase of this trial was terminated early and the IND has been closed.
Clinical trial NCT03037931: Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
Official title: A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
Acronym: HEART-FID
Sponsor: American Regent, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 3065.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-15
Primary completion date: 2023-02-02
Completion date: 2023-02-02
Plan to share individual participant data: NO
Clinical trial NCT04707703: Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
Official title: Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients
Acronym: Isavu-CAPA
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Participant enrollment challenges
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-16
Primary completion date: 2021-10-25
Completion date: 2021-10-25
Plan to share individual participant data: NO
Clinical trial NCT04950504: Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
Official title: A Two-Part 1b/2a Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
Sponsor: COUR Pharmaceutical Development Company, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lagging Enrollment. Opened a separate study.
Enrollment: 9.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-06-02
Primary completion date: 2022-06-24
Completion date: 2022-07-29
Plan to share individual participant data: NO
Clinical trial NCT01783041: Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
Official title: A Double-Blind, Controlled, Randomized Clinical Trial of the Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 144.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-01-31
Primary completion date: 2020-12-31
Completion date: 2021-12-28
Limitations and caveats: This is a single center study.
Clinical trial NCT04326764: Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Official title: A Randomized, Multicenter Phase III Study to Assess the Efficacy of Panobinostat Maintenance Therapy vs. Standard of Care Following Allogeneic Stem Cell Transplantation in Patients With High-risk AML or MDS (ETAL-4 / HOVON-145)
Sponsor: Goethe University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Change of marketing authorisation holder
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-24
Primary completion date: 2023-02-13
Completion date: 2023-02-13
Clinical trial NCT01412333: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Official title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 835.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-09-20
Primary completion date: 2015-05-12
Completion date: 2022-12-30
Baseline population: Intent-to-treat (ITT) population included all randomized participants in the study.
Clinical trial NCT04730427: Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19
Official title: A Phase 1b Study to Investigate the Safety and Preliminary Efficacy of GX-I7 in Patients With COVID-19
Sponsor: Genexine, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-24
Primary completion date: 2022-05-08
Completion date: 2022-07-07
Plan to share individual participant data: NO
Clinical trial NCT04061590: Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
Official title: A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Low Accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-29
Primary completion date: 2023-08-31
Completion date: 2023-08-31
Plan to share individual participant data: NO
Clinical trial NCT04832139: A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device
Official title: A PHASE 1, OPEN-LABEL, RANDOMIZED, 4-PERIOD, 2-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF MARSTACIMAB (PF-06741086) PREFILLED SYRINGE DEVICE AND PREFILLED PEN DEVICE FOLLOWING SUBCUTANEOUS ADMINISTRATION IN HEALTHY ADULT MALE PARTICIPANTS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated due to a change in the benefit/risk assessment for the further administration of marstacimab in a healthy volunteer population.
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-30
Primary completion date: 2021-11-22
Completion date: 2021-11-22
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04262817: The Interaction of Flavor With Nicotine Form in Adult Smokers
Official title: The Interaction of Flavor With Nicotine Form in Adult Smokers
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-01
Primary completion date: 2022-01-10
Completion date: 2022-02-02
Baseline population: Of the 20 participants enrolled, only 16 were randomized and participated in the study.
Clinical trial NCT04873895: TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Official title: Phase 1B Study of Hepatic Chemoembolization Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum
Acronym: TACE-Ax-HCQ
Sponsor: Abramson Cancer Center at Penn Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: failure to accrue
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-01-24
Primary completion date: 2024-04-25
Completion date: 2024-04-25
Plan to share individual participant data: NO
Clinical trial NCT04218071: Actuate 1901: 9-ING-41 in Myelofibrosis
Official title: Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or Combined With Ruxolitinib, in Patients With Myelofibrosis
Sponsor: Actuate Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-20
Primary completion date: 2022-10-13
Completion date: 2024-01-18
Plan to share individual participant data: NO
Clinical trial NCT04657003: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Official title: Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Acronym: SURMOUNT-2
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 938.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-29
Primary completion date: 2023-03-16
Completion date: 2023-04-10
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Time Frame:~Data are available 6 months after the primary publication or approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT02973711: A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
Official title: A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Who Have Achieved a Complete Hematologic Remission, Complete Cytogenetic Remission, and Major Molecular Remission, But Not a Complete Molecular Remission on a Tyrosine Kinase Inhibitor Alone.
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-01-31
Primary completion date: 2021-08-31
Completion date: 2021-08-31
Clinical trial NCT03287414: Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
Official title: A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-20
Primary completion date: 2020-11-25
Completion date: 2022-02-14
Baseline population: Baseline characteristics are provided for all participants who received at least one dose of any study drug
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT02696564: Losartan Effects on Emphysema Progression
Official title: Losartan Effects on Emphysema Progression
Acronym: LEEP
Sponsor: JHSPH Center for Clinical Trials (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 220.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-23
Primary completion date: 2021-03-31
Completion date: 2021-06-30
Plan to share individual participant data: YES
IPD sharing description: NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC)
Clinical trial NCT02978443: A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Official title: A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Sponsor: Georgetown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of Enrollment
Enrollment: 14.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-26
Primary completion date: 2020-07-28
Completion date: 2022-08-02
Plan to share individual participant data: NO
Clinical trial NCT04880642: A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as add-on to Standard of Care in Adult Subjects With COVID-19
Acronym: ATTRACT-3
Sponsor: Vicore Pharma AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 272.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-16
Primary completion date: 2022-04-25
Completion date: 2022-04-25
Plan to share individual participant data: NO
Clinical trial NCT02907918: Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
Official title: A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Acronym: PALTAN
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Futility
Enrollment: 26.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-30
Primary completion date: 2020-08-24
Completion date: 2020-09-23
Plan to share individual participant data: NO
Clinical trial NCT02764801: Contrast-enhanced Ultrasound Evaluation of Chemoembolization
Official title: 2D and 4D Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Chemoembolization
Sponsor: Thomas Jefferson University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 131.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-04-30
Primary completion date: 2021-12-31
Completion date: 2023-02-01
Plan to share individual participant data: NO
Clinical trial NCT04826016: POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer
Official title: A Phase Ib/II Study to Optimize POL6326 (Balixafortide) in Combination With Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer
Acronym: POLTER
Sponsor: MedSIR (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Funder decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-03-16
Primary completion date: 2022-03-16
Completion date: 2022-03-16